Transcriptomic Analysis of Insulin-Sensitive Tissues from Anti-Diabetic Drug Treated ZDF Rats, a T2DM Animal Model

Gene expression changes have been associated with type 2 diabetes mellitus (T2DM); however, the alterations are not fully understood. We investigated the effects of anti-diabetic drugs on gene expression in Zucker diabetic fatty (ZDF) rats using oligonucleotide microarray technology to identify gene expression changes occurring in T2DM. Global gene expression in the pancreas, adipose tissue, skeletal muscle, and liver was profiled from Zucker lean control (ZLC) and anti-diabetic drug treated ZDF rats compared with those in ZDF rats. We showed that anti-diabetic drugs regulate the expression of a large number of genes. We provided a more integrated view of the diabetic changes by examining the gene expression networks. The resulting sub-networks allowed us to identify several biological processes that were significantly enriched by the anti-diabetic drug treatment, including oxidative phosphorylation (OXPHOS), systemic lupus erythematous, and the chemokine signaling pathway. Among them, we found that white adipose tissue from ZDF rats showed decreased expression of a set of OXPHOS genes that were normalized by rosiglitazone treatment accompanied by rescued blood glucose levels. In conclusion, we suggest that alterations in OXPHOS gene expression in white adipose tissue may play a role in the pathogenesis and drug mediated recovery of T2DM through a comprehensive gene expression network study after multi-drug treatment of ZDF rats.

[1]  G. Müller,et al.  The molecular interaction of sulfonylureas with β-cell ATP-sensitive K+-channels , 1995 .

[2]  U. Edvardsson,et al.  Rosiglitazone (BRL49653), a PPARgamma-selective agonist, causes peroxisome proliferator-like liver effects in obese mice. , 1999, Journal of lipid research.

[3]  D. Hardie,et al.  The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. , 2002, Diabetes.

[4]  R. DeFronzo.  Pharmacologic Therapy for Type 2 Diabetes Mellitus , 1999, Annals of Internal Medicine.

[5]  Terence E. Ryan,et al.  Adipose Mitochondrial Biogenesis Is Suppressed in db/db and High-Fat Diet–Fed Mice and Improved by Rosiglitazone , 2007, Diabetes.

[6]  Joseph T. Brozinick,et al.  A Peroxisome Proliferator-Activated Receptor α/γ Dual Agonist with a Unique in Vitro Profile and Potent Glucose and Lipid Effects in Rodent Models of Type 2 Diabetes and Dyslipidemia , 2005 .

[7]  N. York,et al.  Characterization of the Molecular Mode of Action of the Sulfonylurea, Glimepiride, at β-Cells , 1996, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[8]  David Carling,et al.  The Anti-diabetic Drugs Rosiglitazone and Metformin Stimulate AMP-activated Protein Kinase through Distinct Signaling Pathways* , 2002, The Journal of Biological Chemistry.

[9]  J. E. Felíu,et al.  Rosiglitazone-Induced Mitochondrial Biogenesis in White Adipose Tissue Is Independent of Peroxisome Proliferator-Activated Receptor γ Coactivator-1α , 2011, PloS one.

[10]  Krystal L. Edwards,et al.  Implications of Rosiglitazone and Pioglitazone on Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus , 2006, Pharmacotherapy.

[11]  E. Bush,et al.  Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats. , 2001, Metabolism: clinical and experimental.

[12]  M. Kathleen Kerr,et al.  Linear Models for Microarray Data Analysis: Hidden Similarities and Differences , 2003, J. Comput. Biol..

[13]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.

[14]  P. Zimmet.  Globalization, coca‐colonization and the chronic disease epidemic: can the Doomsday scenario be averted? , 2000, Journal of internal medicine.

[15]  D. Loskutoff,et al.  Monocyte chemoattractant protein 1 in obesity and insulin resistance , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Susumu Goto,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..

[17]  C. Bailey.  Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones , 2005, Diabetes, obesity & metabolism.

[18]  L. Goodyear,et al.  5' AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle. , 1999, Diabetes.

[19]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[20]  Dorothy D. Sears,et al.  Multi-tissue, selective PPARγ modulation of insulin sensitivity and metabolic pathways in obese rats. , 2011, American journal of physiology. Endocrinology and metabolism.

[21]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[22]  S. M. Setter,et al.  Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy. , 2003, Clinical therapeutics.

[23]  O. Abdel-Salam,et al.  Effect of rosiglitazone and nateglinide on serum glucose and lipid profile alone or in combination with the biguanide metformin in diabetic rats. , 2006, Pharmacological research.

[24]  C. Kahn,et al.  Insulin signalling and the regulation of glucose and lipid metabolism , 2001, Nature.

[25]  K. Nair,et al.  Gene expression profile in skeletal muscle of type 2 diabetes and the effect of insulin treatment. , 2002, Diabetes.

[26]  E. Marcotte,et al.  Prioritizing candidate disease genes by network-based boosting of genome-wide association data. , 2011, Genome research.

[27]  J. Brozinick,et al.  A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia. , 2005, Molecular endocrinology.

[28]  D. Gerhold,et al.  Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator-activated receptor-gamma agonists. , 2002, Endocrinology.

[29]  Didier Y. R. Stainier,et al.  Cardiac troponin T is essential in sarcomere assembly and cardiac contractility , 2002, Nature Genetics.

[30]  M. Kanaoka,et al.  Global gene expression analysis in liver of obese diabetic db/db mice treated with metformin , 2006, Diabetologia.

[31]  Y. Habib,et al.  Serum electrolytes in diabetic patients and the effect of insulin treatment. , 1959, The Journal of the Egyptian Medical Association.

[32]  Y. Nakaya,et al.  Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis. , 2006, The journal of medical investigation : JMI.

[33]  Z. Bloomgarden,et al.  Inflammation and insulin resistance. , 2003, Diabetes care.

[34]  R. Krall.  Cardiovascular safety of rosiglitazone , 2007, The Lancet.

[35]  G. Bray,et al.  Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo. , 2005, Diabetes.

[36]  A. Butte,et al.  Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Jean-Charles Sanchez,et al.  Effect of rosiglitazone on the differential expression of obesity and insulin resistance associated proteins in lep/lep mice , 2003, Proteomics.

[38]  W. Waldhäusl,et al.  Blood Glucose-Lowering Nuclear Receptor Agonists Only Partially Normalize Hepatic Gene Expression in db/db Mice , 2006, Journal of Pharmacology and Experimental Therapeutics.

[39]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[40]  Ansuman Bagchi,et al.  Gene Expression Profile of Adipocyte Differentiation and Its Regulation by Peroxisome Proliferator-Activated Receptor-γ Agonists. , 2002, Endocrinology.

[41]  A. Häkkinen,et al.  Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. , 2004, Diabetes.

[42]  Laura Herrero,et al.  Obesity, inflammation, and insulin resistance. , 2007, Gastroenterology.

[43]  Hiroyuki Ogata,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..

[44]  D. Isenberg,et al.  Diabetes mellitus complicating systemic lupus erythematosus – analysis of the UCL lupus cohort and review of the literature , 2008, Lupus.

[45]  M. Febbraio,et al.  Chronic rosiglitazone treatment restores AMPKalpha2 activity in insulin-resistant rat skeletal muscle. , 2006, American journal of physiology. Endocrinology and metabolism.

[46]  T. Yoshikawa,et al.  Microarray profiling of gene expression in human adipocytes in response to anthocyanins. , 2006, Biochemical pharmacology.

[47]  Olle Ljunqvist,et al.  Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. , 2002, Diabetes.

[48]  Wenjun Ding,et al.  Effect of vanadate on gene expression of the insulin signaling pathway in skeletal muscle of streptozotocin-induced diabetic rats , 2007, JBIC Journal of Biological Inorganic Chemistry.